Dave Gentry, host of "The RedChip Money Report", interviews Michael Carrel, President and CEO of AtriCure (NASDAQ: ATRC). AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure’s Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure’s AtriClip™ left atrial appendage management (LAAM) exclusion device is the most widely sold device worldwide that’s indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. AtriCure recently acquired nContact, a leader in minimally invasive technology for epicardial ablation. nContact’s mission is to transform the underserved arrhythmia population through a multidisciplinary epicardial-endocardial ablation approach. Afib affects more than 33 million people worldwide.
AtriCure: Innovative Technology for Treatment of Afib - YouTube |
| 4 Likes | 4 Dislikes |
| 3,883 views views | followers |
| Film & Animation | Upload TimePublished on 10 Feb 2016 |
Không có nhận xét nào:
Đăng nhận xét